COMP <GO>
EWTX vs LLY // FREE CASH FLOW YIELD
Edgewise Therapeutics Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: EWTX 3
— LLY 11
▲ FREE CASH FLOW YIELD LEADER: LLY
LAST: $38.90 (-0.03%) • MKT CAP: $4.23B
fcf-yield
-3.41%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
fcf-yield
2.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EWTX VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EWTX | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 83.64% | -42.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -31.90% | 32.36% | -64.26 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -3.41% | 2.30% | -5.71 | LLY | /fcf-yield <GO> |
| Operating Margin | -16.20% | 40.21% | -56.41 | LLY | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 31.90% | -31.90 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | -1.10% | 45.51% | -46.61 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 9.29 | +16.71 | EWTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 9/9 | -6.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.77% | +0.43 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.7 | 77.9 | -32.18 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 0.51 | +0.59 | EWTX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 25.0x | 26.3x | -1.25 | EWTX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.23B | $1.33T | -$1.33T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EWTX REV | LLY REV | EWTX GROSS % | LLY GROSS % | EWTX FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $65.18B | — | 83.0% | -$144.1M | $16.81B |
| FY 2024 | $0 | $45.04B | — | 81.3% | -$110.3M | $8.82B |
| FY 2023 | $0 | $34.12B | — | 79.3% | -$91.9M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EWTX // BETA 1.10
LLY // BETA 0.51